TYRA Chief Operating Officer discloses November insider stock sales

Q: What insider transactions did TYRA report on this Form 4?

The Chief Operating Officer of Tyra Biosciences, Inc. (TYRA) reported several open-market sales of common stock on 11/13/2025 , 11/14/2025 , and 11/17/2025 , with beneficial ownership changing after each transaction.

Q: How many TYRA shares did the COO beneficially own after the reported transactions?

After the final reported transaction on 11/17/2025 , the Chief Operating Officer beneficially owned 296,570 shares of Tyra Biosciences common stock in direct ownership.

Q: What prices were TYRA shares sold for in these insider transactions?

The reported sales used weighted average prices: $16.0036 on 11/13/2025 , $16.0167 on 11/14/2025 , and $16.1098 and $17.0713 on 11/17/2025 , each reflecting multiple trades within narrow price ranges.

Q: What is the reporting person’s role at Tyra Biosciences (TYRA)?

The reporting person is identified as an officer of Tyra Biosciences, Inc. , serving in the role of Chief Operating Officer , and the form is filed by one reporting person.

Q: How are the reported TYRA sale prices described in the filing?

Each reported price is a weighted average sale price for all shares sold in that line item, with the filing noting that actual individual trade prices fell within specified ranges and that detailed breakdowns are available from the issuer upon request.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Tyra Biosciences, Inc. Chief Operating Officer, listed as an officer and sole reporting person, reported multiple open-market sales of common stock. On 11/13/2025, the COO sold 1,111 shares at a weighted average price of $16.0036, leaving 426,870 shares beneficially owned. On 11/14/2025, an additional 110,228 shares were sold at a weighted average price of $16.0167, reducing beneficial ownership to 316,642 shares. On 11/17/2025, the COO reported sales of 18,572 shares at a weighted average price of $16.1098 and 1,500 shares at a weighted average price of $17.0713, resulting in 296,570 shares of common stock beneficially owned following the transactions.

The filing states that all reported sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024, and that the disclosed prices represent weighted averages over multiple trades within specified price ranges.

Insider Trade Summary

Net Seller: 131,411 shares ($2,108,067)

Net Sell 4 txns

Insider Bensen Daniel

Role Chief Operating Officer

Sold 131,411 shs ($2.11M)

Type	Security	Shares	Price	Value
Sale	Common Stock	18,572	$16.1098	$299K
Sale	Common Stock	1,500	$17.0713	$26K
Sale	Common Stock	110,228	$16.0167	$1.77M
Sale	Common Stock	1,111	$16.0036	$18K

Holdings After Transaction: Common Stock — 298,070 shares (Direct)

Footnotes (1)

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.02. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.13. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $17.00. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.06 to $17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Form 4 Insider Transactions: What Each Field Means →

11/17/2025 - 07:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bensen Daniel

(Last)

(First)

(Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD

92008

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/13/2025		S⁽¹⁾		1,111	D	$16.0036⁽²⁾	426,870	D
Common Stock	11/14/2025		S⁽¹⁾		110,228	D	$16.0167⁽³⁾	316,642	D
Common Stock	11/17/2025		S⁽¹⁾		18,572	D	$16.1098⁽⁴⁾	298,070	D
Common Stock	11/17/2025		S⁽¹⁾		1,500	D	$17.0713⁽⁵⁾	296,570	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.02. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.13. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $17.00. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.06 to $17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

	/s/ Ali D. Fawaz, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did TYRA report on this Form 4?

The Chief Operating Officer of Tyra Biosciences, Inc. (TYRA) reported several open-market sales of common stock on 11/13/2025, 11/14/2025, and 11/17/2025, with beneficial ownership changing after each transaction.

How many TYRA shares did the COO beneficially own after the reported transactions?

After the final reported transaction on 11/17/2025, the Chief Operating Officer beneficially owned 296,570 shares of Tyra Biosciences common stock in direct ownership.

What prices were TYRA shares sold for in these insider transactions?

The reported sales used weighted average prices: $16.0036 on 11/13/2025, $16.0167 on 11/14/2025, and $16.1098 and $17.0713 on 11/17/2025, each reflecting multiple trades within narrow price ranges.

Were the TYRA insider stock sales made under a Rule 10b5-1 trading plan?

Yes. The filing states that the sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.

What is the reporting person’s role at Tyra Biosciences (TYRA)?

The reporting person is identified as an officer of Tyra Biosciences, Inc., serving in the role of Chief Operating Officer, and the form is filed by one reporting person.

Did the Form 4 for TYRA report any derivative securities transactions?

No derivative securities transactions are listed in Table II. The reported activity involves non-derivative common stock only, with no derivative acquisitions or dispositions shown.

How are the reported TYRA sale prices described in the filing?

Each reported price is a weighted average sale price for all shares sold in that line item, with the filing noting that actual individual trade prices fell within specified ranges and that detailed breakdowns are available from the issuer upon request.